Hoth Therapeutics (HOTH) Competitors $0.84 +0.01 (+1.20%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends HOTH vs. FBRX, CMMB, BLRX, CLDI, PULM, CTXR, ACXP, BTAI, PIRS, and MIRAShould you be buying Hoth Therapeutics stock or one of its competitors? The main competitors of Hoth Therapeutics include Forte Biosciences (FBRX), Chemomab Therapeutics (CMMB), BioLineRx (BLRX), Calidi Biotherapeutics (CLDI), Pulmatrix (PULM), Citius Pharmaceuticals (CTXR), Acurx Pharmaceuticals (ACXP), BioXcel Therapeutics (BTAI), Pieris Pharmaceuticals (PIRS), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry. Hoth Therapeutics vs. Forte Biosciences Chemomab Therapeutics BioLineRx Calidi Biotherapeutics Pulmatrix Citius Pharmaceuticals Acurx Pharmaceuticals BioXcel Therapeutics Pieris Pharmaceuticals MIRA Pharmaceuticals Forte Biosciences (NASDAQ:FBRX) and Hoth Therapeutics (NASDAQ:HOTH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership and community ranking. Does the media prefer FBRX or HOTH? In the previous week, Forte Biosciences had 9 more articles in the media than Hoth Therapeutics. MarketBeat recorded 12 mentions for Forte Biosciences and 3 mentions for Hoth Therapeutics. Forte Biosciences' average media sentiment score of 0.83 beat Hoth Therapeutics' score of -0.11 indicating that Forte Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hoth Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is FBRX or HOTH more profitable? Hoth Therapeutics' return on equity of -89.68% beat Forte Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Forte BiosciencesN/A -151.43% -118.92% Hoth Therapeutics N/A -89.68%-82.61% Do analysts prefer FBRX or HOTH? Forte Biosciences currently has a consensus target price of $23.58, suggesting a potential upside of 47.40%. Hoth Therapeutics has a consensus target price of $3.50, suggesting a potential upside of 316.67%. Given Hoth Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Hoth Therapeutics is more favorable than Forte Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forte Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Hoth Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Does the MarketBeat Community believe in FBRX or HOTH? Hoth Therapeutics received 43 more outperform votes than Forte Biosciences when rated by MarketBeat users. Likewise, 65.14% of users gave Hoth Therapeutics an outperform vote while only 59.57% of users gave Forte Biosciences an outperform vote. CompanyUnderperformOutperformForte BiosciencesOutperform Votes2859.57% Underperform Votes1940.43% Hoth TherapeuticsOutperform Votes7165.14% Underperform Votes3834.86% Which has higher earnings and valuation, FBRX or HOTH? Forte Biosciences is trading at a lower price-to-earnings ratio than Hoth Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioForte BiosciencesN/AN/A-$31.48M-$16.29-0.98Hoth TherapeuticsN/AN/A-$7.84M-$1.32-0.64 Which has more risk and volatility, FBRX or HOTH? Forte Biosciences has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Comparatively, Hoth Therapeutics has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Do institutionals and insiders believe in FBRX or HOTH? 77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 7.1% of Hoth Therapeutics shares are owned by institutional investors. 9.6% of Forte Biosciences shares are owned by insiders. Comparatively, 10.6% of Hoth Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryHoth Therapeutics beats Forte Biosciences on 12 of the 16 factors compared between the two stocks. Ad Porter & CompanyI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Get Hoth Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOTH vs. The Competition Export to ExcelMetricHoth TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.80M$6.57B$5.22B$8.84BDividend YieldN/A8.14%5.54%4.08%P/E Ratio-0.6411.1296.4017.88Price / SalesN/A356.531,245.5692.88Price / CashN/A53.8241.3136.92Price / Book0.7710.597.226.54Net Income-$7.84M$153.02M$119.86M$226.15M7 Day Performance2.68%3.96%2.14%3.77%1 Month Performance-0.62%-6.72%-2.24%4.46%1 Year Performance-24.32%30.92%32.53%27.57% Hoth Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOTHHoth Therapeutics2.4756 of 5 stars$0.84+1.2%$3.50+316.7%-22.2%$5.80MN/A-0.644FBRXForte Biosciences3.9775 of 5 stars$15.88+1.5%$23.58+48.5%+92,923.3%$23.19MN/A-0.885Insider TradeNews CoverageGap DownCMMBChemomab Therapeutics2.8094 of 5 stars$1.61+0.6%$7.33+355.5%+197.3%$23.12MN/A-1.5820BLRXBioLineRx1.9851 of 5 stars$0.29-10.9%$21.00+7,191.7%-81.7%$23.02M$4.80M-0.7240Analyst ForecastNews CoverageHigh Trading VolumeCLDICalidi Biotherapeutics2.5644 of 5 stars$2.06-4.2%$16.67+709.1%N/A$22.89M$50,000.000.0041PULMPulmatrix0.0694 of 5 stars$6.21+1.6%N/A+230.8%$22.68M$10.01M-2.4420CTXRCitius Pharmaceuticals2.8956 of 5 stars$0.12-25.5%$4.00+3,152.0%-82.6%$22.23MN/A-0.6920Stock SplitNews CoverageGap DownHigh Trading VolumeACXPAcurx Pharmaceuticals2.3954 of 5 stars$1.32+1.2%$12.00+812.5%-64.0%$22.21MN/A-1.193Gap UpBTAIBioXcel Therapeutics4.5623 of 5 stars$0.52-9.7%$5.00+870.9%-86.7%$22.02M$1.38M-0.2690News CoverageGap DownPIRSPieris Pharmaceuticals1.626 of 5 stars$16.58+4.1%N/A+2.8%$21.89M$1.35M-1.33140Analyst UpgradeMIRAMIRA Pharmaceuticals1.6553 of 5 stars$1.29+2.4%$14.00+984.6%-58.7%$21.38MN/A-2.362News Coverage Related Companies and Tools Related Companies Forte Biosciences Alternatives Chemomab Therapeutics Alternatives BioLineRx Alternatives Calidi Biotherapeutics Alternatives Pulmatrix Alternatives Citius Pharmaceuticals Alternatives Acurx Pharmaceuticals Alternatives BioXcel Therapeutics Alternatives Pieris Pharmaceuticals Alternatives MIRA Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HOTH) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hoth Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hoth Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
